Not Tagged
zymeworks
['zymeworks']
our investigational #her2-targeted bispecific antibody drug conjugate (adc) developed using proprietary platform technologies is currently being evaluated in a phase 1 clinical trial for patients with locally advanced or metastatic her2-expressing cancers. #aacr23 
We’re on a mission to bring patients home to their loved ones, disease free.